よむ、つかう、まなぶ。
資料2-4 研究報告の報告状況[960KB] (25 ページ)
出典
公開元URL | https://www.mhlw.go.jp/stf/newpage_53729.html |
出典情報 | 薬事審議会 医薬品等安全対策部会(令和6年度第3回 3/14)《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
研究報告の報告状況
(2024年8月1日~2024年11月30日)
モルヒネ塩酸塩水和物
アヘン
268 アヘンチンキ
アヘン・トコン
アヘンアルカロイド塩酸塩
Harrison S, Capers K, Chen G, Liu JT, Pannu A,
Goodspeed V, et al. New initiation of opioids,
benzodiazepines and antipsychotics following
hospitalization for COVID‐19. J. Hosp. Med.
2024;19(10):877-885
269 リュープロレリン酢酸塩
Matsushima H, Taguchi T, Kodama S, Okubo N, Saito
K, Jabłońska K, et al. Androgen deprivation therapyrelated fracture risk in prostate cancer: an insurance
claims database study in Japan. Journal of Bone and
Mineral Metabolism. 2024;42:223-232
270 3-ヨードベンジルグアニジン(131I)
Matthay KK, Yanik G, Messina J, Quach A, Huberty J,
Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS,
Hawkins RA, Maris JM. Phase II study on the effect of
disease sites, age, and prior therapy on response to
iodine-131-metaiodobenzylguanidine therapy in
refractory neuroblastoma. J Clin Oncol.
2007;25(9)1054-1060.
271 3-ヨードベンジルグアニジン(131I)
Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen
S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R,
Shulkin BL, Jackson H, Goodarzian F, Shimada H,
Courtier J, Hutchinson R, Haas-Koga D, Hasenauer
CB, Czarnecki S, Katzenstein HM, Matthay KK. 131Imetaiodobenzylguanidine with intensive chemotherapy
and autologous stem cell transplantation for high-risk
neuroblastoma. A new approaches to neuroblastoma
therapy (NANT) phase II study. Biol Blood Marrow
Transplant. 2015;21(4)673-681.
272 3-ヨードベンジルグアニジン(131I)
Matthay KK, DeSantes K, Hasegawa B, Huberty J,
Hattner RS, Ablin A, Reynolds CP, Seeger RC,
Weinberg VK, Price D. Phase I dose escalation of 131I
-metaiodobenzylguanidine with autologous bone
marrow support in refractory neuroblastoma. J Clin
Oncol. 1998;16(1)229-236.
273 3-ヨードベンジルグアニジン(131I)
Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio
C, Lanino E, Bertolazzi L, Villavecchia GP, Cabria M,
Scopinaro G, Claudiani F, De Bernardi B. 131Imetaiodobenzylguanidine (131I-MIBG) therapy for
residual neuroblastoma: a mono-institutional experience
with 43 patients. Br J Cancer. 1999;81(8)1378-1384.
274 3-ヨードベンジルグアニジン(131I)
DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F,
Hawkins R, Courtier J, Mosse YP, Matthay KK. Phase
I/II study of (131)I-MIBG with vincristine and 5 days of
irinotecan for advanced neuroblastoma. Br J Cancer.
2015;112(4)644-649.
275 3-ヨードベンジルグアニジン(131I)
Lee JW, Kang ES, Sung KW, Yi E, Lee SH, Yoo KH,
Koo HH. Incorporation of high-dose 131Imetaiodobenzylguanidine treatment into killer
immunoglobulin-like receptor/HLA-ligand mismatched
haploidentical stem cell transplantation for children with
neuroblastoma who failed tandem autologous stem cell
transplantation. Pediatr Blood Cancer. 2017;64(6).
276
ロサルタンカリウム・ヒドロクロロチアジド配
合剤
Castillo-Molina, D. et al.,Antihypertensive drugs and
skin cancer, is there a relationship?,J. Am. Acad.
Dermatol.,2024;91(3):AB124
25/29
(2024年8月1日~2024年11月30日)
モルヒネ塩酸塩水和物
アヘン
268 アヘンチンキ
アヘン・トコン
アヘンアルカロイド塩酸塩
Harrison S, Capers K, Chen G, Liu JT, Pannu A,
Goodspeed V, et al. New initiation of opioids,
benzodiazepines and antipsychotics following
hospitalization for COVID‐19. J. Hosp. Med.
2024;19(10):877-885
269 リュープロレリン酢酸塩
Matsushima H, Taguchi T, Kodama S, Okubo N, Saito
K, Jabłońska K, et al. Androgen deprivation therapyrelated fracture risk in prostate cancer: an insurance
claims database study in Japan. Journal of Bone and
Mineral Metabolism. 2024;42:223-232
270 3-ヨードベンジルグアニジン(131I)
Matthay KK, Yanik G, Messina J, Quach A, Huberty J,
Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS,
Hawkins RA, Maris JM. Phase II study on the effect of
disease sites, age, and prior therapy on response to
iodine-131-metaiodobenzylguanidine therapy in
refractory neuroblastoma. J Clin Oncol.
2007;25(9)1054-1060.
271 3-ヨードベンジルグアニジン(131I)
Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen
S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R,
Shulkin BL, Jackson H, Goodarzian F, Shimada H,
Courtier J, Hutchinson R, Haas-Koga D, Hasenauer
CB, Czarnecki S, Katzenstein HM, Matthay KK. 131Imetaiodobenzylguanidine with intensive chemotherapy
and autologous stem cell transplantation for high-risk
neuroblastoma. A new approaches to neuroblastoma
therapy (NANT) phase II study. Biol Blood Marrow
Transplant. 2015;21(4)673-681.
272 3-ヨードベンジルグアニジン(131I)
Matthay KK, DeSantes K, Hasegawa B, Huberty J,
Hattner RS, Ablin A, Reynolds CP, Seeger RC,
Weinberg VK, Price D. Phase I dose escalation of 131I
-metaiodobenzylguanidine with autologous bone
marrow support in refractory neuroblastoma. J Clin
Oncol. 1998;16(1)229-236.
273 3-ヨードベンジルグアニジン(131I)
Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio
C, Lanino E, Bertolazzi L, Villavecchia GP, Cabria M,
Scopinaro G, Claudiani F, De Bernardi B. 131Imetaiodobenzylguanidine (131I-MIBG) therapy for
residual neuroblastoma: a mono-institutional experience
with 43 patients. Br J Cancer. 1999;81(8)1378-1384.
274 3-ヨードベンジルグアニジン(131I)
DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F,
Hawkins R, Courtier J, Mosse YP, Matthay KK. Phase
I/II study of (131)I-MIBG with vincristine and 5 days of
irinotecan for advanced neuroblastoma. Br J Cancer.
2015;112(4)644-649.
275 3-ヨードベンジルグアニジン(131I)
Lee JW, Kang ES, Sung KW, Yi E, Lee SH, Yoo KH,
Koo HH. Incorporation of high-dose 131Imetaiodobenzylguanidine treatment into killer
immunoglobulin-like receptor/HLA-ligand mismatched
haploidentical stem cell transplantation for children with
neuroblastoma who failed tandem autologous stem cell
transplantation. Pediatr Blood Cancer. 2017;64(6).
276
ロサルタンカリウム・ヒドロクロロチアジド配
合剤
Castillo-Molina, D. et al.,Antihypertensive drugs and
skin cancer, is there a relationship?,J. Am. Acad.
Dermatol.,2024;91(3):AB124
25/29